ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Ep. 264 Contemporary Diagnostics in NMIBC: Clinical Insights with Dr. Anne Schuckman and Dr. Piyush Agarwal"
Episode Synopsis
How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and management of non-muscle invasive bladder cancer (NMIBC)? In the opening episode of our 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt engages in an insightful, in-studio discussion with Dr. Anne Schuckman and Dr. Piyush Agarwal about contemporary strategies and challenges in the diagnosis of non-muscle invasive bladder cancer.
---
This podcast is supported by:
Ferring Pharmaceuticals
---
SYNPOSIS
The doctors emphasize the importance of having an experienced cytopathologist and discuss the use of different biomarkers and imaging modalities in bladder cancer diagnosis. The conversation delves into risk stratification, patient management strategies, and the evolving role of technology and artificial intelligence in enhancing diagnostic accuracy. The experts also share their perspectives on future advancements and their potential impact on clinical practice.
---
TIMESTAMPS
00:00 - Introduction04:05 - Surveillance and Follow-Up Strategies10:10 - Biomarkers in Bladder Cancer18:02 - Blue Light Cystoscopy and Patient Comfort30:56 - Risk Assessment and Counseling42:56 - Future of Bladder Cancer Diagnostics47:00 - Concluding Thoughts
---
RESOURCES
CxBladder Studyhttps://www.sciencedirect.com/science/article/pii/S1078143923000091
Lars Dyrsakjot Study on Tumor Markershttps://pmc.ncbi.nlm.nih.gov/articles/PMC7690647/
The Bridge Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/
---
This podcast is supported by:
Ferring Pharmaceuticals
---
SYNPOSIS
The doctors emphasize the importance of having an experienced cytopathologist and discuss the use of different biomarkers and imaging modalities in bladder cancer diagnosis. The conversation delves into risk stratification, patient management strategies, and the evolving role of technology and artificial intelligence in enhancing diagnostic accuracy. The experts also share their perspectives on future advancements and their potential impact on clinical practice.
---
TIMESTAMPS
00:00 - Introduction04:05 - Surveillance and Follow-Up Strategies10:10 - Biomarkers in Bladder Cancer18:02 - Blue Light Cystoscopy and Patient Comfort30:56 - Risk Assessment and Counseling42:56 - Future of Bladder Cancer Diagnostics47:00 - Concluding Thoughts
---
RESOURCES
CxBladder Studyhttps://www.sciencedirect.com/science/article/pii/S1078143923000091
Lars Dyrsakjot Study on Tumor Markershttps://pmc.ncbi.nlm.nih.gov/articles/PMC7690647/
The Bridge Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/
In God we trust